About the Company
We do not have any company description for Prevail Therapeutics Inc at the moment.
Exchange
NASDAQ/NMS (GLOBAL MARKET)
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $PRVL News
Eli Lilly to Buy Prevail Therapeutics in $1.04 Billion Deal, Shares Soar
According to the deal, Lilly will commence a tender offer to acquire all outstanding shares of Prevail Therapeutics Inc. for a purchase price of $22.50 per share in cash. The deal is expected to ...
Why Prevail Therapeutics (PRVL) Stock Might be a Great Pick
One stock that might be an intriguing choice for investors right now Prevail Therapeutics Inc. PRVL. This is because this security in the Medical - Generic Drugs space is seeing solid earnings ...
E-mini S&P 500 Index (ES) Futures Technical Analysis – Strengthens Over 3664.00, Weakens Under 3645.25
In stock related news, Eli Lilly and Co rose 2.1% after the company said it would buy Prevail Therapeutics Inc in a deal potentially valued at $1.04 billion, to expand its presence in the ...
Kintara Therapeutics Inc KTRA
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
CVKD Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart ...
Bristol Myers Squibb Completes Acquisition of PureTech's Founded Entity Karuna Therapeutics for $14 Billion
NDAQ:PRTC) Bristol Myers Squibb Completes Acquisition of PureTech's Founded Entity Karuna Therapeutics for $14 Billion ...
UC study: Subcutaneous infusion pump safe, effective for Parkinson’s treatment
HS reports consultancy fees from Novo Nordisk, Blue Rock Therapeutics, and Neurocrine; clinical trial support from Insightec, Sun Pharmaceuticals, Prevail ... Denali, INC Research, IPMDS, Lundbeck ...
Intellia Therapeutics Inc NTLA
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
LXEO Lexeo Therapeutics, Inc.
Lexeo Therapeutics, Inc. operates as a clinical-stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy ...
Q4 2023 Intellia Therapeutics Inc Earnings Call
Ian Karp; SVP, IR and Corporate Communications; Intellia Therapeutics Inc John Leonard; President & CEO; Intellia Therapeutics Inc David Lebwohl; Chief Medical Officer; Intellia Therapeutics Inc ...
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q4 2023 Earnings Call Transcript
Intellia Therapeutics, Inc. beats earnings expectations ... to be in a position to be highly competitive and ultimately prevail. Kostas Biliouris: Thank you very helpful. Operator: The next ...
Loading the latest forecasts...